Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2022 | $10.00 | Buy | Roth Capital |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Roth Capital initiated coverage of Creative Medical Tech with a rating of Buy and set a new price target of $10.00
Fastest customizable press release news feed in the world
PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate
PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company's history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative stem cell therapies across multiple indications. At the
PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel wi
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability. This designation positions CELZ-201-DDT among a select group of therapies recognized for their potential to address serious medical conditions with high unmet need. Fast Track status enables the Company to benefit from accelerated FDA int
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, "Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity." Once granted, the patent will be in effect until at least 2040. The patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes using the ImmCelzTM product, which includes the supercharged T
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, "Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells." Once granted, the patent will be in effect until at least 2040. The patent has broad claims to treat patients who are at risk of developing or who already have heart failure with the Company's proprietary Imm
PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded dose escalation for its ongoing Phase 1/2 trial of StemSpine® using AlloStem™ (CELZ-201-DDT), the Company's proprietary allogeneic (donor) cell therapy for chronic lower back pain caused by degenerative disc disease (DDD). This regulatory milestone follows compelling interim blinded data demonstrating statistically significant pain reduction and improved mobility among trial participants. The first-of-its-kin
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 837,104 shares of common stock of the Company originally issued in October 2024 at their current exercise price of $4.42 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-283091). The aggregate gross proceeds
PHOENIX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a leading biotechnology innovator in regenerative medicine, enthusiastically supports President Donald J. Trump's executive order expanding access to in vitro fertilization (IVF). This initiative directly aligns with the company's vision to transform reproductive health through its groundbreaking OvaStem® program, which has demonstrated an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient's own eggs—all with no safety concerns at up to five years post-treatment. Patients with Primary Ovarian Insufficiency (POI) typically face only a
PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a pioneering biotechnology firm specializing in regenerative medicine solutions for immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced compelling mid-term follow-up data from its StemSpine® pilot study utilizing its AlloStem™ cells for the treatment of chronic lower back pain. The pilot study demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility. Notably, over 90% of patients reported no opioid use for pain management three year
10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
10-K/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
424B3 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
EFFECT - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
10-K/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
S-3 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
10-K/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
DEF 14A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
Live Leadership Updates
PHOENIX, Ariz. , March 2, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative Medical Technology more than 15 years of healthcare leadership experience in sales, marketing, and business development. He most recently served
This live feed shows all institutional transactions in real time.
SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)